HOME >> BIOLOGY >> NEWS
Breast cancer follow-ups 'no longer guess-work' thanks to new physics research

As the number of breast cancer patients rises, and hospitals struggle to meet the growing cost of healthcare provision, new research by physicists could help divert funds into frontline treatment such as chemotherapy drugs and better imaging technology.

Breast cancer is the most common form of cancer in England and Wales and one in nine women will develop breast cancer at some point in their lives. Research published today (Monday 1st March 2004) in the Institute of Physics journal Physics in Medicine & Biology reveals a new technique that will help doctors to judge more accurately how long they should continue to see patients following successful treatment of breast cancer. Doctors currently see patients for follow-up examinations for up to ten years in order to check for recurrence of the tumour. Until now, this length time (the "follow-up period") has been guess-work by doctors, and is generally much longer than necessary.

Dr. Richard Mould, the lead author of the paper, said: "Doctors tend to follow-up cancer patients for much longer than is really necessary, using hospital resources that could be better spent on frontline treatment such as chemotherapy drugs and better imaging technology in hospitals."

He continued: "This is the first time scientists have produced a formal way of calculating a precise length of follow-up needed, and it can be specific to a particular hospital or region. Our study suggests that follow up times can be reduced from ten years to four years without significantly reducing our ability to detect local tumour reccurrance. This means that six years worth of a physician's time and outpatient clinic costs could instead be diverted to parts of the treatment process where it would do more good."

Using data taken from a series of patients with T1 and T2 stage (primary tumours up to 5cm in greatest dimension) breast cancer from the Institut Curie in Paris, Dr. Mould developed a model which involves calcu
'"/>

Contact: David Reid
david.reid@iop.org
44-207-470-4815
Institute of Physics
1-Mar-2004


Page: 1 2

Related biology news :

1. Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane
2. Breastfeeding decreases infant mortality
3. Breast cancer study suggests role for tissue in carcinogenesis
4. Breast self examination increases womens concerns but has no effect on mortality
5. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
6. The 4th European Breast Cancer Conference (EBCC4)
7. Breast cancer susceptibility genes play role in DNA repair
8. Breast cancer can be reversed in laboratory mice, scientists report
9. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
10. Breast fluid a better option for detecting cancer
11. Breastfeeding may compensate for harmful effects of smoking during pregnancy

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Breast cancer follow ups longer guess work thanks new physics research

(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/25/2014)... 2014 The report “Service Quality Management ... & Provider Type - Global Advancements, Worldwide Forecasts & ... in-depth analysis and forecasting of revenues. , Browse ... pages and in-depth TOC on “Service Quality Management (SQM) ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
Cached News: